Pulmonary Drug Delivery Devices Market (Product - Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers; Application - Asthma, COPD, Cystic Fibrosis; Distribution Channel - Retail Pharmacies, Hospital Pharmacies, E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2030

Growing prevalence of chronic respiratory diseases is one of the key factors anticipated to accelerate demand for pulmonary drug delivery systems (PDDS) in coming years

As per a report published by the Global Asthma Network (GAN), in 2014, 334 million cases has been diagnosed across the globe. Growing incidence of respiratory diseases has resulted in increase in patient population. This, in turn, has resulted in increase in fuelled demand for pulmonary drug delivery devices. Subsequently, growing demand rate is boosting the global pulmonary drug delivery devices market.

Further, technological advancements in the field is projected to provide lucrative opportunities for expansion of the market.

Meanwhile, drawback of conventional treatment methods such as low efficacy and late onset of action is the key development areas. Research and development activities aiming to develop novel targeted drug delivery devices is likely to provide new growth avenues for widening of the pulmonary drug delivery devices market in coming years.

At the same time, growing number of initiatives undertaken by government bodies and non-government organizations is, further, contributing to the market growth in terms of revenue. For example, CDC’s National Asthma Control Program (NACP) is allotting funds for raising awareness regarding asthma among people as well as the affected patients.

Rising awareness regarding asthma is expected to boost the adoption rate of pulmonary drug delivery devices for treatment of the asthma and Chronic Obstructive Pulmonary Diseases (COPD). This, in turn, result in growth of the global market.

North America Market is anticipated to lead in the global pulmonary drug delivery devices market in coming years. Prominence of the region is attributed to increasing cases of affected people and growing demand for diagnostic devices.

the global pulmonary drug delivery devices market for the historical period 2017–2018 and forecast period 2019–2027, ‘increase in the prevalence and incidence of respiratory diseases across globe, increasing population of smokers across countries, rising prescription of the combination therapies, and rising research & development in the asthma & COPD treatment’ are projected to drive the global pulmonary drug delivery devices market.

According to the report, the global pulmonary drug delivery devices market was valued at US$ 36,159.9 Mn in 2018 and is projected to expand at a CAGR of 2.7% from 2019 to 2027.

Increase in prevalence and incidence of respiratory diseases: Key Drivers

Chronic obstructive pulmonary disease (COPD) is an umbrella term used to describe various progressive lung diseases such as emphysema, chronic bronchitis, refractory asthma, and others. Patients suffering from severe COPD require continuous supply of oxygen. Often symptoms such as increased breathlessness and coughing are ignored as a normal sign of aging; however, these are the early signs of COPD. According to WHO, COPD is the fourth-leading cause of death globally, with approximately 2.75 million deaths per annum. According to the CDC, over 16 million people in the U.S. are living with respiratory disorders, such as lung cancer, COPD, and heart diseases, caused due to smoking. Around 100 million adults are estimated to be suffering from COPD indication, and these statistics are expected to drive the pulmonary drug delivery devices market.

According to the United Nations, the geriatric population of people above the age of 60 is expected to double by 2050, and triple by 2100, which means that it is projected to rise from 962 million in 2017 to 2.1 billion in 2050 and reach 3.1 billion by 2100. Globally, the geriatric population is increasing at a faster pace than that of the younger age group, the present geriatric population of 962 million is about 13% of the global population and is increasing at a rate of about 3% every year. Furthermore, the number of persons age 80 years or above is estimated to be triple by 2050, an increase from 137 million in 2017 to 425 million by 2050.

The number of smokers is also increasing globally. The U.S. has seen a decline in the percentage of people smoking; however, there are still 40 million adults who smoke and 20 million will die prematurely unless they quit. Also, exposure to secondhand smoke raises complications for people suffering from asthma and COPD. According to the American Lung Association, exposure to secondhand smoke can cause more than 202,000 asthma flare-ups among children each year.

Low Cost Generic Competition Likely To Hamper Market: Key Restraint

Patent loss of branded drugs in the pulmo0nary drug delivery devices market provides a platform for the entry of generic drugs. Generics are generally priced lower than their equivalent branded drugs which attract large number of patients in low- and middle-income countries where the prevalence of pulmonary diseases is high as per the data provided by WHO, thus increase in generic drugs in the pulmonary drug delivery devices market will lead to decline in revenues. Moreover, patent loss of drugs such as Advair Diskus (GSK) during the forecast period will hit the market drastically and increase competitive scenario in the generic as well as branded drugs market.

Global Pulmonary drug delivery devices Market: Competitive Landscape

This report profiles major players in the global Pulmonary drug delivery devices market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global pulmonary drug delivery devices market is fragmented, with the presence of a number of international, regional players as well as local players. Various players operating in the global pulmonary drug delivery devices market are

• Boehringer Ingelheim GmbH
• Novartis AG
• GlaxoSmithKline plc
• AstraZeneca plc
• Teva Pharmaceutical Industries Ltd
•  Merck & Co., Inc
•  MannKind Corporation,
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Omron Corporation
• 3M Healthcare
• Sunovion Pharmaceuticals, Inc
• Koninklijke Philips N.V.
• PARI GmbH
• Nypro Healthcare Inc. (Jabil Circuit Inc.)

Key Questions Answered in Global Pulmonary Drug Delivery Devices Market Report

• What is the scope of growth of product companies in the global pulmonary drug delivery devices Market?
• What will be the Y-o-Y growth of the global pulmonary drug delivery devices market between 2019 and 2027?
• What is the influence of growing disease prevalence on the global pulmonary drug delivery devices market?
• What are the technological advancements for the treatment of the pulmonary drug delivery devices condition?
• Which region continue to be the most profitable market for pulmonary drug delivery devices market?
• Which factors are anticipated to hamper the growth of the global pulmonary drug delivery devices market during the forecast period?
• Which are the leading companies in the global pulmonary drug delivery devices market?

Global Pulmonary Drug Delivery Devices Market - Segmentation

Product

• Dry Powder Inhaler
• Metered Dose Inhaler
• Nebulizers

Application

• Cystic Fibrosis
• Others

Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• E-commerce

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pulmonary Drug Delivery Devices Market  

4. Market Overview

    4.1. Introduction

        4.1.1. Market Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Pulmonary Drug Delivery Devices Market   Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter Five Forces Analysis

5. Key Insights

    5.1. Disease Prevalence across Region/Globally

    5.2.  Pipeline Analysis 

    5.3. Technological Advancements

6. Global Pulmonary Drug Delivery Devices Market   Analysis and Forecast, by Product    

    6.1. Introduction & Definition

        6.1.1. Key Findings / Developments

    6.2. Global Pulmonary Drug Delivery Devices Market   Value Forecast, by Product  , 2017–2027

        6.2.1. Dry Powder Inhaler

        6.2.2. Metered Dose Inhaler

        6.2.3. Nebulizers

    6.3. Global Pulmonary Drug Delivery Devices Market  Attractiveness, by Product   

7. Global Pulmonary Drug Delivery Devices Market   Analysis and Forecast, by Application

    7.1. Introduction & Definition

        7.1.1. Key Findings / Developments

    7.2. Global Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        7.2.1. Asthma

        7.2.2. COPD

        7.2.3. Cystic fibrosis

        7.2.4. Others

8. Global Pulmonary Drug Delivery Devices Market   Analysis and Forecast, by Distribution Channel 

    8.1. Introduction & Definition

        8.1.1. Key Findings / Developments

    8.2. Global Pulmonary Drug Delivery Devices Market   Value Forecast, by Distribution Channel , 2017–2027

        8.2.1. Hospital Pharmacies     

        8.2.2. Retail Pharmacies   

        8.2.3. E-commerce 

    8.3. Global Pulmonary Drug Delivery Devices Market   Attractiveness, by Distribution Channel   

9. Global Pulmonary Drug Delivery Devices Market   Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Pulmonary Drug Delivery Devices Market   Value Forecast, by Region

        9.2.1. North America 

        9.2.2. Europe 

        9.2.3. Asia Pacific 

        9.2.4. Latin America 

        9.2.5. Middle East & Africa 

    9.3. Global  Pulmonary Drug Delivery Devices Market   Attractiveness, by Region

10. North America Pulmonary Drug Delivery Devices Market   Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Product   , 2017–2027

        10.2.1. Dry Powder Inhaler

        10.2.2. Metered Dose Inhaler

        10.2.3. Nebulizers

    10.3. North America Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        10.3.1. Asthma

        10.3.2. COPD

        10.3.3. Cystic fibrosis

        10.3.4. Others

    10.4. North America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Distribution Channel  , 2017–2027

        10.4.1. Hospital Pharmacies     

        10.4.2. Retail Pharmacies   

        10.4.3. E-commerce  

    10.5. North America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Country, 2017–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Pulmonary Drug Delivery Devices Market   Attractiveness Analysis 

        10.6.1. By Product    

        10.6.2. Application

        10.6.3. By Distribution Channel   

        10.6.4. By Country

11. Europe Pulmonary Drug Delivery Devices Market   Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Product   , 2017–2027

        11.2.1. Dry Powder Inhaler

        11.2.2. Metered Dose Inhaler

        11.2.3. Nebulizers 

    11.3. Europe Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        11.3.1. Asthma

        11.3.2. COPD

        11.3.3. Cystic fibrosis

        11.3.4. Others

    11.4. Europe Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Distribution Channel  , 2017–2027

        11.4.1. Hospital Pharmacies     

        11.4.2. Retail Pharmacies   

        11.4.3. E-commerce  

    11.5. Europe Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe 

    11.6. Europe Pulmonary Drug Delivery Devices Market   Attractiveness Analysis 

        11.6.1. By Product   

        11.6.2. Application

        11.6.3. By Distribution Channel   

        11.6.4. By Country/Sub-region

12. Asia Pacific Pulmonary Drug Delivery Devices Market   Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Product   , 2017–2027

        12.2.1. Dry Powder Inhaler

        12.2.2. Metered Dose Inhaler

        12.2.3. Nebulizers

    12.3. Asia Pacific Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        12.3.1. Asthma

        12.3.2. COPD

        12.3.3. Cystic fibrosis

        12.3.4. Others

    12.4. Asia Pacific Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Distribution Channel  , 2017–2027

        12.4.1. Hospital Pharmacies     

        12.4.2. Retail Pharmacies   

        12.4.3. E-commerce  

    12.5. Asia Pacific Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific 

    12.6. Asia Pacific Pulmonary Drug Delivery Devices Market   Attractiveness Analysis 

        12.6.1. By Product   

        12.6.2. Application

        12.6.3. By Distribution Channel   

        12.6.4. By Country/Sub-region

13. Latin America Pulmonary Drug Delivery Devices Market   Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Product   , 2017–2027

        13.2.1. Dry Powder Inhaler

        13.2.2. Metered Dose Inhaler

        13.2.3. Nebulizers

    13.3. Latin America Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        13.3.1. Asthma

        13.3.2. COPD

        13.3.3. Cystic fibrosis

        13.3.4. Others

    13.4. Latin America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Distribution Channel  , 2017–2027

        13.4.1. Hospital Pharmacies     

        13.4.2. Retail Pharmacies   

        13.4.3. E-commerce  

    13.5. Latin America Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America 

    13.6. Latin America Pulmonary Drug Delivery Devices Market   Attractiveness Analysis 

        13.6.1. By Product   

        13.6.2. Application

        13.6.3. By Distribution Channel   

        13.6.4. By Country/Sub-region

14. Middle East & Africa Pulmonary Drug Delivery Devices Market   Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Product   , 2017–2027

        14.2.1. Dry Powder Inhaler

        14.2.2. Metered Dose Inhaler

        14.2.3. Nebulizers 

    14.3. Middle East & Africa Pulmonary Drug Delivery Devices Market   Value Forecast, by Application , 2017–2027

        14.3.1. Asthma

        14.3.2. COPD

        14.3.3. Cystic fibrosis

        14.3.4. Others

    14.4. Middle East & Africa Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Distribution Channel  , 2017–2027

        14.4.1. Hospital Pharmacies     

        14.4.2. Retail Pharmacies   

        14.4.3. E-commerce  

    14.5. Middle East & Africa Pulmonary Drug Delivery Devices Market   Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa 

    14.6. Middle East & Africa Pulmonary Drug Delivery Devices Market   Attractiveness Analysis 

        14.6.1. By Product   

        14.6.2. Application

        14.6.3. By Distribution Channel   

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Share Analysis

    15.2. Company Profiles

        15.2.1. 3M

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Financial Overview 

            15.2.1.3. Growth Strategies

            15.2.1.4. SWOT Analysis

        15.2.2. BMG Pharma 

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Growth Strategies

            15.2.2.3. SWOT Analysis

        15.2.3. ConvaTec Inc

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Financial Overview 

            15.2.3.3. Growth Strategies

            15.2.3.4. SWOT Analysis

        15.2.4. Integra Life Sciences

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Financial Overview 

            15.2.4.3. Growth Strategies

            15.2.4.4. SWOT Analysis

        15.2.5. Intermed Pharmaceuticals

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Financial Overview 

            15.2.5.3. Growth Strategies

            15.2.5.4. SWOT Analysis

        15.2.6. Molnlycke Health Care AB

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Financial Overview 

            15.2.6.3. Growth Strategies

            15.2.6.4. SWOT Analysis

        15.2.7. Smith & Nephew 

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Financial Overview 

            15.2.7.3. Growth Strategies

            15.2.7.4. SWOT Analysis

        15.2.8. Stratpharma AG

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Growth Strategies

            15.2.8.3. SWOT Analysis